Caribou Biosciences (CRBU) Amortizatization of Intangibles (2021 - 2026)
Caribou Biosciences (CRBU) posted quarterly Amortizatization of Intangibles of $269000.0 for Q1 2026, down 40.49% year-over-year from $452000.0 in Q1 2025, and up 68.12% quarter-over-quarter from $160000.0 in Q4 2025.
Caribou Biosciences (CRBU) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Amortizatization of Intangibles for 6 consecutive years, with $269000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 40.49% year-over-year to $269000.0; the TTM figure through Mar 2026 stood at $957000.0 (down 73.7% YoY), while the FY2025 annual figure was $1.1 million, down 75.88% from the prior year.
- Amortizatization of Intangibles grew to $269000.0 in Q1 2026 per CRBU's latest filing, from $160000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $2.4 million in Q3 2023 and bottomed at -$1.6 million in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $668058.8 across 5 years, with a median of $452000.0 in 2025.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles surged 1836.54% — and 2023, when it slumped 279.07%.
- Caribou Biosciences' Amortizatization of Intangibles stood at $903000.0 in 2022, then plunged by 279.07% to -$1.6 million in 2023, then jumped by 162.96% to $1.0 million in 2024, then sank by 84.28% to $160000.0 in 2025, then surged by 68.12% to $269000.0 in 2026.
- Business Quant data shows CRBU's Amortizatization of Intangibles at $269000.0 in Q1 2026, $160000.0 in Q4 2025, and $235000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44,000.00 |
| Jun 30, 2026 | 44,000.00 |
| Mar 31, 2026 | 269,000.00 |
| Mar 31, 2026 | 269,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Dec 31, 2025 | 160,000.00 |
| Sep 30, 2025 | 235,000.00 |
| Sep 30, 2025 | 235,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Mar 31, 2025 | 452,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 946,000.00 |
| Jun 30, 2024 | 946,000.00 |
| Mar 31, 2024 | 1.54 Mn |
| Mar 31, 2024 | 1.54 Mn |